Clinical trial of PRCN 323 in children with adrenoleucodystrophy.
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 12 May 2014
Price : $35 *
At a glance
- Drugs PRCN 323 (Primary)
- Indications Adrenoleucodystrophy
- Focus Adverse reactions
- Sponsors Neuralgene
- 12 May 2014 New trial record
- 29 Apr 2014 The first patient has been treated and this trial will be expanded to more patients, according to a Neuralgene media release.